McGowan Ian, Anton Peter
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Curr Opin HIV AIDS. 2008 Sep;3(5):593-8. doi: 10.1097/COH.0b013e32830891cf.
This review will summarize the rationale for developing rectal microbicides and discuss recent developments in the preclinical and clinical evaluation of these products.
It is clear that heterosexual women often engage in anal intercourse and that men who have sex with men can be found in both the developed and developing world. These observations have catalyzed the need to assess rectal safety of vaginal products and develop rectal specific microbicides. New approaches to the preclinical evaluation of rectal microbicides include the use of transgenic mice, nonhuman primate studies, and human colorectal explant systems. The design of phase I rectal safety studies is becoming increasingly sophisticated, including safety biomarkers to evaluate microbicide-induced immunotoxicity.
There is growing acceptance that all vaginal microbicide candidates moving towards effectiveness studies should be evaluated for rectal safety. In addition, there is increasing awareness of the need to develop rectal specific microbicide formulations.
本综述将总结开发直肠用杀微生物剂的基本原理,并讨论这些产品在临床前和临床评估方面的最新进展。
很明显,异性恋女性经常进行肛交,并且在发达国家和发展中国家都能发现男男性行为者。这些观察结果促使人们有必要评估阴道产品的直肠安全性,并开发直肠专用杀微生物剂。直肠用杀微生物剂临床前评估的新方法包括使用转基因小鼠、非人灵长类动物研究和人类结肠外植体系统。I期直肠安全性研究的设计正变得越来越复杂,包括用于评估杀微生物剂诱导的免疫毒性的安全生物标志物。
越来越多的人接受这样的观点,即所有进入有效性研究阶段的阴道杀微生物剂候选产品都应进行直肠安全性评估。此外,人们越来越意识到需要开发直肠专用的杀微生物剂配方。